Symptoms of Low Resveratrol: Causes and Treatment
Deficiency
Symptoms & causes
Resveratrol is a plant polyphenol, not an essential nutrient — no deficiency syndrome exists, and the 'low resveratrol' framing reflects supplement marketing, not clinical medicine.
Resveratrol is a non-essential phytonutrient found in red grapes, berries, and peanuts. Unlike vitamins or minerals, your body has no dietary requirement for it, and no clinical deficiency state has ever been identified. While preclinical studies showed promise for metabolic health and longevity, human trials have been inconsistent, and high-dose supplements introduce drug interaction risks that don't exist with food-level intake.
This is general nutrition and wellness information, not medical advice. If you're on a weight-loss medication or managing a health condition, confirm specifics with your clinician.
Symptoms of low Resveratrol — a stilbene polyphenol produced by plants (especially grapes, berries, peanuts, and Japanese knotweed root) under environmental stress; a non-essential phytonutrient. Primary dietary sources: red wine, grape skin, blueberries, peanuts.
Everyday signs are on the left; the ones on the right mean it's time to check in with a clinician.
Everyday signs
Common symptoms
- None specific to low resveratrol intake; no deficiency phenotype has been characterized in humans.
Don't wait
See a doctor if
- Not applicable to deficiency. Supplement concern: high-dose resveratrol may interact with anticoagulants (warfarin) and CYP3A4-metabolized drugs.
Who is most likely to run low
Some people are more prone to falling short than others — including many people on a weight-loss journey who are simply eating less.
- No deficiency population exists. Resveratrol bioavailability is low and variable; much is metabolized rapidly post-absorption.
What causes low Resveratrol — a stilbene polyphenol produced by plants (especially grapes, berries, peanuts, and Japanese knotweed root) under environmental stress; a non-essential phytonutrient. Primary dietary sources: red wine, grape skin, blueberries, peanuts.
- Not applicable to true deficiency. Lower intake is associated with minimal consumption of red wine, grapes, and berries.
How low levels are diagnosed
No recognized diagnostic test exists for resveratrol levels, and none is clinically indicated.
How it's corrected
Most gaps close with food first, and supplementation when a clinician recommends it.
Not applicable for deficiency. Food sources include red wine (skin of red grapes), blueberries, raspberries, mulberries, peanuts, dark chocolate, and Japanese knotweed. Supplement formulations typically use trans-resveratrol in doses of 150 to 500 mg per day in clinical trials.
How to keep levels up
Not applicable.
When to see a clinician
Not applicable to deficiency. If taking high-dose resveratrol supplements, discuss with a clinician or pharmacist if you are on anticoagulants or medications metabolized by CYP enzymes.
Resveratrol Is Not a Nutrient: Why 'Deficiency' Is the Wrong Question
If you've searched for 'symptoms of low resveratrol,' you've already encountered a framing problem — one created by the supplement industry, not by clinical science. Resveratrol is a stilbene polyphenol, a compound plants produce under environmental stress, not a vitamin, mineral, or essential fatty acid your body requires to function.
No governmental or scientific body — not the NIH, the Institute of Medicine, or the European Food Safety Authority — has established a Recommended Dietary Allowance (RDA), Adequate Intake (AI), or Estimated Average Requirement (EAR) for resveratrol. There is no deficiency syndrome, no deficiency symptoms, and no diagnostic test for low resveratrol because your body operates normally with zero dietary intake.
The idea that you might be 'deficient' traces back to the 'French Paradox' hypothesis popularized in the 1990s — the observation that French populations had relatively low rates of cardiovascular disease despite diets rich in saturated fat, a phenomenon speculatively attributed to red wine consumption and, by extension, resveratrol. This narrative, compelling as it was, has not held up in controlled human trials. Subsequent research suggests the original observation was confounded by multiple factors, including underreporting of heart disease deaths, differences in diagnostic practices, and the fact that the dietary pattern studied was from an earlier period.
Supplement marketers seized on the French Paradox story and the early preclinical data — mostly cell-culture and animal studies showing resveratrol activated sirtuins and extended lifespan in yeast, worms, and fish — to build a consumer narrative around deficiency and replacement. The logic was simple and profitable: if resveratrol is associated with health benefits, then not taking it must represent a deficit. But association is not causation, and the absence of a non-essential phytonutrient is not a deficiency.
Bottom line
Unlike vitamins or essential fatty acids, your body functions normally with zero dietary resveratrol — no deficiency state exists, and the 'French Paradox' story has not held up in controlled trials.
The Biology: What Resveratrol Actually Does in Lab Studies vs Humans
To understand why the resveratrol story has been so durable despite weak human evidence, you need to understand the gap between preclinical and clinical data — and it's one of the widest in nutrition science.
In cell cultures and animal models, resveratrol demonstrates genuinely impressive biological activity. It activates SIRT1, a sirtuin protein associated with cellular stress resistance and longevity pathways. It stimulates AMP-activated protein kinase (AMPK), a master metabolic regulator that influences glucose uptake and fatty acid oxidation. It inhibits cyclooxygenase (COX) enzymes, reducing inflammatory signaling. It scavenges free radicals directly and upregulates endogenous antioxidant defenses. In mice fed high-fat diets, resveratrol supplementation improved insulin sensitivity, reduced inflammatory markers, and extended lifespan in some — though not all — studies.
The problem is translation. Resveratrol has notoriously poor bioavailability in humans. When ingested orally, it is rapidly and extensively metabolized in the liver and gut — primarily into glucuronide and sulfate conjugates — before reaching systemic circulation. The parent compound, trans-resveratrol, which is responsible for most of the biological activity seen in lab studies, reaches peak plasma concentrations that are a tiny fraction of the ingested dose. Much of what circulates is in conjugated forms with uncertain biological activity.
This bioavailability bottleneck means that the concentrations used to produce effects in cell studies — often 10 to 100 micromolar — are essentially impossible to achieve in human plasma through oral supplementation. Human trials have repeatedly shown that while resveratrol metabolites can be detected after supplementation, the clinical effects on endpoints like inflammation, insulin sensitivity, and cardiovascular risk factors are inconsistent, small in magnitude, and often statistically non-significant.
A 2014 meta-analysis published in JAMA Internal Medicine examined resveratrol's effect on cardiovascular risk factors and found no significant benefit on any outcome, including blood pressure, lipid profiles, or inflammatory markers. More recent systematic reviews have echoed this finding: the signal is weak, the effect sizes are small, and the evidence does not support resveratrol supplementation for cardiovascular disease prevention or treatment.
Bottom line
The gap between animal/cell data and human RCT data for resveratrol is one of the widest in nutrition science — understanding this prevents false hope.
Resveratrol and Metabolic Health: What the Human Trials Found
Given the preclinical data on AMPK activation and insulin sensitivity, resveratrol was a natural candidate for metabolic health trials — obesity, type 2 diabetes, non-alcoholic fatty liver disease. The results have been mixed at best.
Some small trials have reported modest improvements. A 2011 study in obese men found that 150 mg per day of trans-resveratrol for 30 days produced changes in metabolic markers that partially mimicked calorie restriction, including reduced sleeping metabolic rate and improved insulin sensitivity. A 2013 trial in patients with type 2 diabetes reported that 1 gram per day for 45 days modestly reduced fasting glucose and insulin resistance. A few studies have noted small reductions in systolic blood pressure in specific subgroups.
But these positive signals are counterbalanced by multiple null trials. A 2014 study in overweight, insulin-resistant subjects found no effect of resveratrol on insulin sensitivity, body composition, or resting metabolic rate at doses up to 2 grams per day. A 2016 trial in patients with non-alcoholic fatty liver disease found no improvement in liver histology or metabolic parameters. The largest and most rigorous trials trend toward null results, and publication bias likely inflates the apparent proportion of positive studies.
For weight loss specifically, the evidence is essentially absent. No large, well-controlled trial has demonstrated that resveratrol supplementation produces clinically meaningful weight loss in humans. The metabolic improvements seen in some studies are small and inconsistent, and they do not translate into the kind of body-weight changes that would matter to a patient. If you are taking a GLP-1 receptor agonist for weight loss, resveratrol is not a substitute, an enhancer, or a maintenance strategy with any evidence base.
Bottom line
Human trial data is inconsistent; the clinically meaningful effects seen in preclinical work have not reliably translated to RCTs in humans, particularly for weight loss.
Drug Interactions and Safety: The Risks Supplement Brands Don't Highlight
The safety profile of resveratrol at dietary intake levels — the amounts you get from eating grapes or drinking a glass of red wine — is unremarkable. But the doses used in supplements, typically 150 to 500 milligrams per day and sometimes exceeding 1 gram, are orders of magnitude higher than dietary exposure. At these doses, resveratrol becomes pharmacologically active in ways that can interfere with prescription medications.
The primary concern is cytochrome P450 enzyme inhibition. In vitro and some in vivo studies indicate that resveratrol inhibits CYP3A4 and CYP2C9, two liver enzymes responsible for metabolizing a substantial fraction of prescription drugs. CYP3A4 metabolizes many statins (atorvastatin, simvastatin), calcium channel blockers, and certain anti-arrhythmics. CYP2C9 metabolizes warfarin, a commonly prescribed anticoagulant with a narrow therapeutic window. Inhibition of these enzymes can increase drug plasma concentrations, potentially leading to toxicity or, in the case of warfarin, elevated INR and bleeding risk.
Resveratrol also exhibits estrogenic activity at high concentrations, binding to estrogen receptors and modulating estrogen-responsive gene expression. This raises theoretical concerns for individuals with hormone-sensitive cancers — breast, ovarian, endometrial — though human data on this risk is limited. The precautionary principle suggests avoidance of high-dose resveratrol supplements in these populations.
Gastrointestinal side effects — nausea, diarrhea, abdominal cramping — are reported at doses above 1 gram per day. These are generally mild and self-limiting but can be distressing and may compound the GI side effects that some GLP-1 users already experience during dose titration. For a patient already managing nausea from semaglutide or tirzepatide, adding a supplement with its own GI side-effect profile is rarely worth the unproven benefit.
Bottom line
High-dose resveratrol supplements carry drug interaction risks that are absent from food-level resveratrol intake — and GLP-1 users often take multiple medications.
Resveratrol and GLP-1 Therapy: Mechanistic Overlap and Honest Expectations
It's tempting to look at the metabolic pathways resveratrol targets — SIRT1, AMPK, inflammatory cascades — and see a natural complement to GLP-1 receptor agonists, which work through incretin signaling, appetite suppression, and delayed gastric emptying. The pathways do overlap in broad terms: both influence energy metabolism, both modulate inflammation, both have been studied in the context of insulin resistance. But mechanistic overlap in a diagram is not clinical synergy in a patient.
No human trial has tested whether adding resveratrol to a GLP-1 receptor agonist improves weight loss, glycemic control, or cardiovascular outcomes beyond what the GLP-1 drug achieves alone. The null hypothesis — that resveratrol adds nothing — has not been disproven because it has barely been tested. In the absence of evidence, assuming benefit is speculation, not science.
There is also a practical concern specific to GLP-1 users. One of the most commonly cited dietary sources of resveratrol is red wine. But red wine delivers resveratrol in a package that includes alcohol — a source of empty calories, a potential trigger for reflux (which GLP-1 drugs can exacerbate), and a substance that can affect liver function and blood glucose. For someone using a GLP-1 agonist to lose weight and improve metabolic health, adding alcohol for the sake of resveratrol intake is counterproductive. The resveratrol content of red wine is also modest — roughly 0.2 to 2 milligrams per 5-ounce glass — making it an inefficient delivery vehicle.
If you are on semaglutide, tirzepatide, or another GLP-1 medication and are considering resveratrol supplementation, the honest assessment is this: there is no evidence it helps, there is a non-zero risk of drug interactions, and the money and attention are better directed toward interventions with proven benefit — dietary quality, physical activity, sleep, and medication adherence.
Bottom line
There is no evidence that resveratrol supplementation enhances GLP-1 therapy in humans; mechanistic overlap does not equal clinical synergy.
What most pages leave out
Resveratrol is one of the most over-marketed supplements in the weight-loss and anti-aging space. The honest framing: bioavailability is poor, human RCT data is inconsistent, the 'French Paradox' has not been validated in controlled trials, and the supplement form creates drug interaction risks absent from food sources. Healthline often presents the anti-aging/weight-loss angle without adequate caveat on the human trial failure.
We flag this so you can make an informed choice — not to scare you off.
❓Frequently Asked Questions
There are none. Resveratrol is a non-essential phytonutrient — your body does not require it to function, and no clinical deficiency syndrome has ever been identified. The concept of 'low resveratrol' is a marketing construct, not a medical diagnosis.
Human clinical trial evidence does not support resveratrol as a weight-loss intervention. While some small studies have reported modest metabolic improvements, the effect sizes are small and inconsistent, and no large, well-controlled trial has demonstrated clinically meaningful weight loss. It is not a substitute for evidence-based weight management.
The primary dietary sources are the skin of red grapes, red wine, blueberries, raspberries, mulberries, peanuts, and Japanese knotweed root. Dark chocolate also contains small amounts. The resveratrol content varies widely based on plant variety, growing conditions, and processing.
A 5-ounce glass of red wine typically contains between 0.2 and 2 milligrams of resveratrol, depending on grape variety, region, and winemaking techniques. This is far below the 150 to 500 milligram doses used in most clinical trials, making wine an impractical source for achieving supplement-level intake.
Yes, at high supplemental doses. Resveratrol inhibits CYP3A4 and CYP2C9 enzymes, which metabolize many common medications including certain statins, calcium channel blockers, and warfarin. This can increase drug plasma levels and potentially lead to adverse effects. Discuss resveratrol supplementation with your clinician or pharmacist if you take prescription medications.
Yes, resveratrol has demonstrated antioxidant, anti-inflammatory, and SIRT1-activating properties in laboratory studies. However, the extent to which these effects occur in the human body after oral supplementation is less clear due to poor bioavailability and rapid metabolism.
Clinical trials have most commonly used doses of 150 to 500 milligrams per day of trans-resveratrol, the bioactive form. There is no established optimal dose, and safety data above 1 gram per day is limited. Given the inconsistent human evidence, there is no evidence-based dose recommendation for any health outcome.
There is no established benefit to combining resveratrol with GLP-1 medications, and the potential for drug interactions — particularly if you take other medications metabolized by CYP enzymes — makes caution appropriate. Discuss any supplement use with the clinician managing your GLP-1 therapy.
Medically reviewed by
Chet Tharpe, MDBoard-certified physician
Last reviewed July 2026
Related Articles
What Are the Symptoms of Low Aloe Vera? Causes and Treatment
Aloe vera is a plant, not a nutrient—no deficiency exists. Learn the critical gel vs. latex safety distinction, FDA actions, and oral use risks for GLP-1 users.
Read moreSymptoms of Low Barley Grass: Why This Isn’t a Real Deficiency
Barley grass is a plant food, not an essential nutrient. There is no barley grass deficiency. Learn what it actually contains, what the weak evidence shows, and the real safety risks.
Read moreSymptoms of Low 5-HTP (5-Hydroxytryptophan): Causes & Treatment
5-HTP is a serotonin precursor, not a nutrient you can be deficient in. Learn what low serotonin activity means, the real risks of 5-HTP supplements, and safer alternatives.
Read moreSymptoms of Low Astaxanthin: Causes and Treatment
Astaxanthin is a powerful antioxidant found in salmon and shrimp, but there's no such thing as a deficiency. Learn what low intake actually means and what the science says.
Read moreSymptoms of Low Apple Cider Vinegar: Causes and Treatment
Apple cider vinegar is a condiment, not a nutrient — no deficiency syndrome exists. Learn what the research actually shows about ACV, blood sugar, and safety risks.
Read moreSymptoms of Low Ashwagandha: Causes and Treatment
Ashwagandha is an adaptogenic herb, not a nutrient. No deficiency syndrome exists. Learn what the evidence shows for stress, thyroid, and safety risks like thyrotoxicosis.
Read moreOn a GLP-1, or thinking about one?
Nutrient gaps are more common on a GLP-1 because you eat less — care that includes real clinical oversight helps you do it safely.Curex connects you with licensed clinicians for compounded GLP-1 medications, if it's right for you.
- Compounded semaglutide from $49/mo, tirzepatide from $149/mo
- Prescribed by licensed clinicians after an online visit
- Delivered to your door — no in-person clinic required
This content is for general informational purposes only and is not medical or nutritional advice, a diagnosis, or a substitute for professional judgment. It does not account for your health, medications, or goals, and nutrition information changes over time. Always talk with a qualified clinician or dietitian before making significant changes to your diet, supplements, or medications. Curex offers compounded GLP-1 medications through licensed clinicians and does not sell or endorse the food or supplement reviewed on this page.